Search

Lynch syndrome - caused by pathogenic germline MLH1, MSH2, MSH2, PMS2, or EPCAM variants - is among the most common forms of inherited cancer susceptibility and predisposes to high risks of colorectal cancer, endometrial cancer, and other malignancies. We also eagerly await data from the CaPP3 trial of 1882 Lynch syndrome carriers, which will address the primary question about whether lower aspirin doses (100 mg/day and 300 mg/day) are non-inferior to 600 mg/day in reducing Lynch syndrome-associated colorectal cancer incidence. 378, 2011, 2081-2087 5 J Burn, H Sheth, F Elliott, Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. [Extracted from the article]